MX391071B - Conjugados de un resto de il-7 y un polímero. - Google Patents
Conjugados de un resto de il-7 y un polímero.Info
- Publication number
- MX391071B MX391071B MX2017011562A MX2017011562A MX391071B MX 391071 B MX391071 B MX 391071B MX 2017011562 A MX2017011562 A MX 2017011562A MX 2017011562 A MX2017011562 A MX 2017011562A MX 391071 B MX391071 B MX 391071B
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- polymer
- moilarity
- nonpeptidic
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131634P | 2015-03-11 | 2015-03-11 | |
| PCT/US2016/022146 WO2016145388A1 (en) | 2015-03-11 | 2016-03-11 | Conjugates of an il-7 moiety and an polymer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017011562A MX2017011562A (es) | 2018-05-11 |
| MX391071B true MX391071B (es) | 2025-03-21 |
Family
ID=56878892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011562A MX391071B (es) | 2015-03-11 | 2016-03-11 | Conjugados de un resto de il-7 y un polímero. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190290733A1 (https=) |
| EP (1) | EP3285799A4 (https=) |
| JP (3) | JP2018510863A (https=) |
| KR (2) | KR20170125839A (https=) |
| CN (1) | CN107405384A (https=) |
| AU (1) | AU2016228555B2 (https=) |
| CA (1) | CA2978330C (https=) |
| IL (1) | IL254389B2 (https=) |
| MA (1) | MA41957A (https=) |
| MX (1) | MX391071B (https=) |
| WO (1) | WO2016145388A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
| CA2664304C (en) | 2006-09-28 | 2017-08-22 | Schering Corporation | Use of pegylated il-10 to treat cancer |
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| EP3068425B1 (en) | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| CA2986755A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| US10398761B2 (en) | 2015-08-25 | 2019-09-03 | Armo Biosciences, Inc. | Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers |
| WO2020121071A1 (en) * | 2018-12-12 | 2020-06-18 | Levim Biotech Llp | Acylation process for preparation of n-substituted peptide |
| WO2022020637A1 (en) * | 2020-07-22 | 2022-01-27 | Nektar Therapeutics | Il-7 receptor agonist composition and related methods and uses |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| AU2002307497A1 (en) * | 2001-04-23 | 2002-11-05 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
| AP2004003050A0 (en) * | 2001-11-20 | 2004-06-30 | Pharmacia Corp | Chemically modified human growth hormone conjugates |
| EP1391513A1 (en) * | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
| NZ541122A (en) * | 2002-12-26 | 2008-09-26 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| CN101072793B (zh) * | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| CA2711503A1 (en) * | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| ES2866674T3 (es) * | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| US9375465B2 (en) * | 2011-11-14 | 2016-06-28 | Emory University | Conjugates of GM-CSF and IL-7, compositions and methods related thereto |
-
2016
- 2016-03-11 MA MA041957A patent/MA41957A/fr unknown
- 2016-03-11 CN CN201680014816.7A patent/CN107405384A/zh active Pending
- 2016-03-11 EP EP16762659.7A patent/EP3285799A4/en active Pending
- 2016-03-11 US US15/556,996 patent/US20190290733A1/en active Pending
- 2016-03-11 IL IL254389A patent/IL254389B2/en unknown
- 2016-03-11 KR KR1020177024937A patent/KR20170125839A/ko not_active Ceased
- 2016-03-11 WO PCT/US2016/022146 patent/WO2016145388A1/en not_active Ceased
- 2016-03-11 AU AU2016228555A patent/AU2016228555B2/en active Active
- 2016-03-11 CA CA2978330A patent/CA2978330C/en active Active
- 2016-03-11 JP JP2017547157A patent/JP2018510863A/ja not_active Withdrawn
- 2016-03-11 MX MX2017011562A patent/MX391071B/es unknown
- 2016-03-11 KR KR1020257010980A patent/KR20250052471A/ko active Pending
-
2021
- 2021-03-01 JP JP2021031726A patent/JP2021091708A/ja active Pending
-
2022
- 2022-08-16 JP JP2022129624A patent/JP2022163194A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170125839A (ko) | 2017-11-15 |
| JP2021091708A (ja) | 2021-06-17 |
| AU2016228555A1 (en) | 2017-08-31 |
| EP3285799A1 (en) | 2018-02-28 |
| MA41957A (fr) | 2018-02-28 |
| CA2978330C (en) | 2024-01-09 |
| US20190290733A1 (en) | 2019-09-26 |
| MX2017011562A (es) | 2018-05-11 |
| IL254389B (en) | 2022-11-01 |
| JP2018510863A (ja) | 2018-04-19 |
| WO2016145388A1 (en) | 2016-09-15 |
| JP2022163194A (ja) | 2022-10-25 |
| AU2016228555B2 (en) | 2021-12-23 |
| IL254389B2 (en) | 2023-03-01 |
| CA2978330A1 (en) | 2016-09-15 |
| IL254389A0 (en) | 2017-11-30 |
| KR20250052471A (ko) | 2025-04-18 |
| CN107405384A (zh) | 2017-11-28 |
| EP3285799A4 (en) | 2018-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388865B (es) | Conjugados de un resto de interleucina-15 (il-15) y un polimero. | |
| MX391071B (es) | Conjugados de un resto de il-7 y un polímero. | |
| IL268888A (en) | Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, cea, or claudin-18.2 | |
| MX388465B (es) | Conjugados de un resto de interleucina-2 y un polímero. | |
| CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
| EA201891211A1 (ru) | Ингибиторы cxcr2 | |
| MX382791B (es) | Conjugados novedosos de glicano y uso de los mismos | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| UY34789A (es) | ?picolinamidas macrocíclicas como fungicidas, composiciones que los comprenden y método de control y prevención de ataque fúngico?. | |
| CY1123574T1 (el) | Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων | |
| MX376824B (es) | 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj). | |
| MX2016009943A (es) | Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares. | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| HUE058662T2 (hu) | Ciklikus dinukleotidok mint rákellenes szerek | |
| UY36500A (es) | Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas | |
| MX390725B (es) | Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado. | |
| MX2020004133A (es) | Oligosacaridos inmunomoduladores. | |
| WO2013020079A3 (en) | Conjugates of an il-11 moiety and a polymer | |
| MX392293B (es) | Composición química de ácido hialurónico | |
| EP3300501A4 (en) | Novel compositions, uses and methods of making the same | |
| EP3478663A4 (en) | LACTAM-FUNCTIONALIZED POLYMER, COMPOSITIONS AND APPLICATIONS THEREOF | |
| CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων | |
| CY1124457T1 (el) | Συνθεση για τη θεραπεια του βηχα | |
| KR20180084936A (ko) | 중합체 조성물 및 그로부터 형성된 핫-멜트 접착제 | |
| MX389107B (es) | Detergente en tableta para lavavajillas y metodos de fabricacion y de utilizacion del mismo. |